Literature DB >> 36252282

Exosomes in malignant pleural effusion from lung cancer patients impaired the cytotoxicity of double-negative T cells.

Jingjing Wu1, Ranran Zhu2, Zhengxia Wang1, Xueqin Chen1, Tingting Xu1, Yanan Liu1, Meijuan Song1, Jingxian Jiang1, Qiyun Ma1, Zhongqi Chen1, Yuan Liu3, Xiaoyue Wang4, Mingshun Zhang5, Mao Huang6, Ningfei Ji7.   

Abstract

CD3+CD4-CD8- double-negative T (DNT) cells are new weapons in cancer immunotherapy. Here, we explored DNT cells in malignant pleural effusions (MPEs) from lung cancer patients. DNT cells, especially TCRαβ+CD56- DNT cells, were increased in MPE from lung cancer patients. DNT cells highly expressed PD-1, TRAIL, NKG2D and DNAM-1. In contrast, FasL was barely detected in DNT cells. Compared with non-MPE cells, MPE-derived DNT cells expressed much higher levels of PD-1 and TRAIL. DNT cells from healthy peripheral blood donors potentially killed lung cancers, which was decreased by MPE supernatant. Exosomes from MPE supernatant expressed PD-1 and CEACAM1 and impaired the cytotoxicity of DNT cells. Blocking PD-1 and TIM3 rescued the cytotoxicity of DNT cells treated with MPE-derived exosomes. Overall, we demonstrated that the frequency of DNT cells in MPE from lung cancer patients was increased and that MPE-derived exosomes impaired the cytotoxicity of DNT cells via the PD-1/PD-L1 and CEACAM1/TIM3 pathways.
Copyright © 2022. Published by Elsevier Inc.

Entities:  

Year:  2022        PMID: 36252282      PMCID: PMC9579705          DOI: 10.1016/j.tranon.2022.101564

Source DB:  PubMed          Journal:  Transl Oncol        ISSN: 1936-5233            Impact factor:   4.803


  37 in total

1.  The DNA methylation signature of human TCRαβ+CD4-CD8- double negative T cells reveals CG demethylation and a unique epigenetic architecture permissive to a broad stimulatory immune response.

Authors:  Paul A Renauer; Patrick Coit; Amr H Sawalha
Journal:  Clin Immunol       Date:  2014-10-29       Impact factor: 3.969

2.  Lactate dehydrogenase and serum tumor markers for predicting metastatic status in geriatric patients with lung adenocarcinoma.

Authors:  Xiaolu Ren; Yixun Zhang; Yi Lyu; Baoli Jin; Hongxia Guo; Jing Wu; Xiaomin Li; Xuejun Liu
Journal:  Cancer Biomark       Date:  2019       Impact factor: 4.388

3.  A phase I trial of adoptive transfer of allogeneic natural killer cells in patients with advanced non-small cell lung cancer.

Authors:  Eleni G Iliopoulou; Panteleimon Kountourakis; Michalis V Karamouzis; Dimitrios Doufexis; Alexandros Ardavanis; Constantin N Baxevanis; Gerasimos Rigatos; Michael Papamichail; Sonia A Perez
Journal:  Cancer Immunol Immunother       Date:  2010-08-12       Impact factor: 6.968

4.  Cancer statistics, 2022.

Authors:  Rebecca L Siegel; Kimberly D Miller; Hannah E Fuchs; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2022-01-12       Impact factor: 508.702

5.  Allogeneic Human Double Negative T Cells as a Novel Immunotherapy for Acute Myeloid Leukemia and Its Underlying Mechanisms.

Authors:  JongBok Lee; Mark D Minden; Weihsu C Chen; Elena Streck; Branson Chen; Hyeonjeong Kang; Andrea Arruda; Dalam Ly; Sandy D Der; Sohyeong Kang; Paulina Achita; Cheryl D'Souza; Yueyang Li; Richard W Childs; John E Dick; Li Zhang
Journal:  Clin Cancer Res       Date:  2017-10-26       Impact factor: 12.531

6.  Helper T cells down-regulate CD4 expression upon chronic stimulation giving rise to double-negative T cells.

Authors:  Inna V Grishkan; Achilles Ntranos; Peter A Calabresi; Anne R Gocke
Journal:  Cell Immunol       Date:  2013-07-02       Impact factor: 4.868

Review 7.  DNT Cell-based Immunotherapy: Progress and Applications.

Authors:  Yingrui Li; Kang Dong; Xueke Fan; Jun Xie; Miao Wang; Songtao Fu; Qin Li
Journal:  J Cancer       Date:  2020-03-31       Impact factor: 4.207

Review 8.  Progress on pivotal role and application of exosome in lung cancer carcinogenesis, diagnosis, therapy and prognosis.

Authors:  Ming-Yue Li; Li-Zhong Liu; Ming Dong
Journal:  Mol Cancer       Date:  2021-01-27       Impact factor: 27.401

Review 9.  Dendritic cells loaded with tumor derived exosomes for cancer immunotherapy.

Authors:  Hongyu Liu; Ling Chen; Yaojun Peng; Songyan Yu; Jialin Liu; Liangliang Wu; Lijun Zhang; Qiyan Wu; Xin Chang; Xinguang Yu; Tianyi Liu
Journal:  Oncotarget       Date:  2017-09-11

Review 10.  Immunotherapy (excluding checkpoint inhibitors) for stage I to III non-small cell lung cancer treated with surgery or radiotherapy with curative intent.

Authors:  Jianwei Zhu; Rui Li; Eva Tiselius; Raheleh Roudi; Olivia Teghararian; Chen Suo; Huan Song
Journal:  Cochrane Database Syst Rev       Date:  2017-12-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.